Rapha Inc

HEALTH CENTER CLUSTER

HEALTH CENTER CLUSTER

AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS

HEALTH INFRASTRUCTURE INVESTMENT PROGRAM

FY 2021 ENDING THE HIV EPIDEMIC - PRIMARY CARE HIV PREVENTION - RAPHAEL HEALTH CENTER (RHC) IS A FEDERALLY QUALIFIED HEALTH CENTER IN INDIANAPOLIS AND WAS ESTABLISHED IN 1994. RHC’S SERVICE AREA IS ABOUT 7% OF THE MARION COUNTY, INDIANA POPULATION AND SERVED 5,568 UNIQUE PATIENTS IN 2020. WE ARE UNIQUE IN THAT WE OFFER A FULL RANGE OF INTEGRATED CARE SERVICES, INCLUDING PRIMARY CARE, BEHAVIORAL HEALTH, DENTAL AND OPTOMETRY. THE MAJORITY OF OUR PATIENTS RESIDE IN THREE ZIP CODES: 46205, 46218, 46208. THIS PARTICULAR GEOGRAPHIC AREA HAS LIMITED RESOURCES INCLUDING LACK OF HIGHER PAYING JOBS, ACCESS TO HEALTHY FOODS AND AFFORDABLE AND SAFE HOUSING. IN MARION COUNTY, 15.2% OF RESIDENTS AND 19.4% OF CHILDREN LIVE BELOW THE FEDERAL POVERTY LINE. THE LACK OF NEEDED RESOURCES HAS LED TO POOR HEALTH INDICATORS FOR MANY OF OUR PATIENTS. ALTHOUGH THERE ARE LOCAL HIV RESOURCES WITHIN THE INDIANAPOLIS METRO AREA, THE SURGE OF STD AND HEP C CASES IN MARION COUNTY INDICATES THERE IS MORE NEED THAN WHAT IS CURRENTLY AVAILABLE. ACCORDING TO THE MARION COUNTY PUBLIC HEALTH DIRECTOR, DR. CAINE, THE RATE OF REPORTED ACUTE HEPATITIS C INFECTION IN MARION COUNTY ROSE FROM 0.6 TO 7.6 PER 100,000 POPULATION BETWEEN 2013 AND 2017. AT LEAST 86 PERCENT OF THE NEW CASES IN 2017, PATIENTS REPORTED INJECTING DRUGS WITHIN THE LAST SIX MONTHS, AND AT LEAST 58 PERCENT REPORTED SHARING DRUGS AND PARAPHERNALIA. THE CDC ESTIMATES A PREVALENCE BETWEEN 9,200 AND 11,400 CASES OF CHRONIC HEPATITIS C FOR A POPULATION OF MARION COUNTY’S SIZE. HIV CASES HAVE ALSO SPIKED. THIS BACKGROUND SUBSTANTIATES A STRONG NEED TO IMPLEMENT HIV PREVENTION AND TREATMENT SERVICES ONSITE AT RAPHAEL HEALTH CENTER. RAPHAEL CURRENTLY TESTS AND CONNECTS HIV POSITIVE PATIENTS TO SERVICES. HOWEVER, WE ARE PROPOSING TO IMPLEMENT A BRAND-NEW HIV PROGRAM FOR RAPHAEL HEALTH CENTER TO TARGET AT RISK AND DIAGNOSED HIV PATIENTS AND COMMUNITY MEMBERS. THE RHC PROGRAM WILL FOCUS ON PROVIDING TESTING TO AT RISK PATIENTS THAT WILL BE IDENTIFIED THOUGH A SCREENING PROCESS. OUR ELE CTRONIC MEDICAL RECORDS SOFTWARE CALLED AZARA IDENTIFIED 2,09 ELIGIBLE PATIENTS TO BE SCREENED FOR HIV. FROM 1/2019 TO 12/2019, RHC TESTED 1,065 PATIENTS. WE BELIEVE THAT THERE ARE ALSO MORE INDIVIDUALS IN OUR COMMUNITY THAT ARE AT RISK AND WOULD COME TO RHC FOR HIV SERVICES IF THEY ARE MADE AWARE OF THIS NEW OPPORTUNITY. FOR THE PROSED PROGRAM, WE ANTICIPATE HIRING A FULL-TIME PROGRAM COORDINATOR THAT WILL OVERSEE OUTREACH, EDUCATION AND EVALUATION OF THE PROGRAM AND ITS PATIENTS.THE PROGRAM COORDINATOR WILL WORK IN TANDEM WITH OUR MEDICAL PROVIDERS TO PRESCRIBE PREP AND LINK PATIENTS TO INTEGRATED CARE SERVICES; INCLUDING OVERSEEING COUNSELING AND EDUCATION OF PATIENTS. A TREATMENT PLAN WILL BE CREATED FOR EACH PATIENT BASED ON SCREENING AND DIAGNOSES. IN EFFORT TO FURTHER SUPPORT THE MANAGEMENT OF THE PATIENT’S HEALTH AND WELL-BEING, WE WILL ALSO HIRE A COMMUNITY HEALTH WORKER (CHW). THIS PROGRAM WILL INCLUDE AN .5 FTE MEDICAL PROVIDER TO SUPPORT THE CLINICAL NEEDS OF THE PROGRAM, INCLUDING ASSESSING PATIENT RISK FACTORS AND IDENTIFYING THEIR NEED FOR, AND PRESCRIBING PREP. WITH RHC’S GOAL TO MARKEDLY INCREASE ITS HIV SCREENING, ASSESSMENT AND INITIATING PREP FOR THE FIRST TIME, WE UNDERSTAND THE NEED FOR EDUCATION AND TRAINING OF STAFF AND PROVIDERS SUPPORTING THE PROGRAM. THEREFORE, WE WILL INCLUDE STAFF TRAINING DOLLARS IN THE BUDGET. MANY OF OUR PATIENTS ALREADY EXPERIENCE BARRIERS SUCH AS TRANSPORTATION THAT HINDERS THEIR ABILITY TO MAKE IT TO SCHEDULED MEDICAL APPOINTMENTS. TO ALLEVIATE THAT BARRIER FOR PROGRAM PARTICIPANTS, AN IMPORTANT AIM IS TO PROVIDE FUNDS TO COVER RIDES TO AND FROM APPOINTMENTS VIA LYFT,UBER AND PUBLIC TRANSPORTATION. RHC ‘S GOAL IS TO PROVIDE PREP TESTING TO 10% (APPROXIMATELY 565 OF OUR PATIENTS) OF OUR PATIENT POPULATION THAT IS AT RISK FOR CONTRACTING, OR DIAGNOSED WITH HIV. OUR GOAL WOULD BE TO SUPPORT AT LEAST 600 INDIVIDUALS THAT WOULD NEED HIV PREVENTION OR TREATMENT SERVICE AND OFFE

HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING

HEALTH CENTER INFRASTRUCTURE SUPPORT

SUPPORTING SAFE & EQUITABLE RELATIONSHIPS: A SCHOOL-BASED ADVOCACY & HTRA EXPANSION PROJECT

DEVELOPMENT OF SMALL MOLECULE EPIGENETIC THERAPEUTICS FOR PROSTATE CANCER - IN THIS ADMINISTRATIVE SUPPLEMENT PROPOSAL, WE FORM A THREE-TEAM MEMBER TO PARTICIPATE I-CORPS PROGRAM. OUR TEAM CONSISTS OF DR. ZHI-PING LIU (C-LEVEL CORPORATE OFFICER), DR. QING-JUN ZHANG (TECHNICAL LEAD), AND MR. KELLEN RAGSDALE (INDUSTRY EXPERT). DR. LIU IS THE SCIENTIFIC CO-FOUNDER OF RAPHAEL PHARMACEUTICALS LLC, THE GRANTEE SMALL BUSINESS. DR. LIU’S LAB ESTABLISHED KDM4B AS A TARGET FOR PROSTATE TUMORIGENESIS AND IDENTIFIED LEAD COMPOUNDS B3 AND ITS ANALOGS. SHE IS ONE OF THE INVENTORS OF OUR TECHNOLOGY, USE OF KDM4B INHIBITORS IN PROSTATE CANCER THERAPY, AND PI OF THE STTR PHASE I GRANT. DR. LIU WILL LEAD THE THREE-MEMBER TEAM AND IMPLEMENT THE OVERALL COMMERCIALIZATION STRATEGY FOR THE PROJECT BASED ON KNOWLEDGE GAINED DURING THE I-CORPS PROGRAM. DR. ZHANG HAS BEEN TRAINED AS POST-DOC WITH DR. LIU AND IS NOW A SENIOR RESEARCH SCIENTIST IN HER LAB AND TECHNICAL LEAD IN RAPHAEL PHARMACEUTICALS. DR. ZHANG HAS SCIENTIFIC BACKGROUND IN EPIGENETICS, NUCLEAR HORMONE RECEPTORS, CANCER, AND TRANSCRIPTIONAL REGULATION. HIS EXPERTISE AND WORK IN EPIGENETICS CONTRIBUTED SIGNIFICANTLY TO OUR PROJECT DEVELOPMENT. DR. ZHANG HAS PARTICIPATED IN ALL ASPECTS OF THE DEVELOPMENT OF KDM4B INHIBITORS IN DR. LIU’S LAB AND IS INTIMATELY FAMILIAR WITH THE TECHNOLOGY. MR. RAGSDALE WAS A BUSINESS DEVELOPMENT MANAGER AT UT SOUTHWESTERN MEDICAL CENTER. HE IS A RECOGNIZED EXPERT IN COMMERCIALIZING MEDTECH AND BIOTECH PRODUCTS AND SEASONED INDEPENDENT CONSULTANT WHO HELPS HIS CLIENTS WITH THEIR IP NEEDS IN ALL ASPECTS OF EARLY- STAGE TECHNOLOGY, PRODUCT DEVELOPMENT, AND BUSINESS CREATION. MR. RAGSDALE HAD EXTENSIVE MEETINGS WITH THE TECHNOLOGY INVENTOR DR. ZHI-PING LIU ON THE PROJECT AND IS VERY ENTHUSIASTIC AND COMMITTED TO THE PROJECT. ALL TEAM MEMBERS ARE COMMITTED TO THE PROGRAM AND ABLE TO MEET THE TIME-INTENSIVE REQUIREMENTS OF THE TRAINING PROGRAM. OUR TECHNOLOGY HAS BEEN FILED FOR PATENT PROTECTION. THE AIM OF THE PROPOSAL IS TO LEARN FROM THE I-CORPS PROGRAM HOW TO CONDUCT BACKGROUND RESEARCH INTO COMPETITIVE IP LANDSCAPE, VALUE PROPOSITION, MARKET ASSESSMENT, REIMBURSEMENT MODEL, AND IDENTIFYING COMMERCIALIZATION PATHWAY. WE ARE WILLING TO MODIFY, REALIGN, AND PIVOTING OUR INITIAL COMMERCIALIZATION STRATEGY BASED ON THOROUGH INTERVIEW WITH POTENTIAL CUSTOMERS AND INDUSTRY EXPERTS AND KNOWLEDGE GAINED FROM THE PROGRAM.

HIGHER EDUCATION EMERGENCY RELIEF FUND (HEERF) II PROPRIETARY INSTITUTION GRANT FUNDS FOR STUDENTS (CFDA 84.425Q) (A) (4)

ARRA - CAPITAL IMPROVEMENT PROGRAM

EDUCATION STABILIZATION FUND FOR STUDENTS EDUCATION DISRUPTED BY THE COVID-19 PANDEMIC.

RAPHAEL'S ALLIANCE INSTITUTION COVID-19

FUNDING FOR STUDENTS IMPACTED BY COVID-19

FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT)

RAPHAEL'S SCHOOL OF BEAUTY CULTURE, INC. STUDENT COVID-19

RAPHAEL'S NILES HEERF COVID-19

EDUCATION STABILIZATION FUND FOR STUDENTS EDUCATION IMPACTED BY THE COVID-19 VIRUS

ARRA - INCREASE SERVICES TO HEALTH CENTERS

HEALTH CARE AND OTHER FACILITIES

FY 2023 EXPANDING COVID-19 VACCINATION

HEERF FOR INSTITUTIONS COVID-19

HEERF FOR STUDENTS IMPACTED BY COVID-19 PANDEMIC

FY 2020 CORONAVIRUS SUPPLEMENTAL FUNDING FOR HEALTH CENTERS

RCDG - VALUE-ADDED PRODUCT MARKET DEVELOPMENT GRANTS

SEC 9007 REAP-RENEW ENERGY SYSTEMS GRANTS, $20,000 OR LESS (MAN)

SEC 9007 REAP-RENEW ENERGY SYSTEMS GRANTS, $20,000 OR LESS (MAN)

FY 2023 BRIDGE ACCESS PROGRAM

FAMILY VIOLENCE PREVENTION FORUM FOR MINORITY/IMMIGRANT COMMUNITY MEMBERS

HEALTH INFRASTRUCTURE INVESTMENT PROGRAM

BI GRANTS - RCDG MANDATORY VALUE ADDED PRODUCT MARKETING DVLP